The American Society of Clinical Oncology announced during its Chicago meeting that a drug has the potential of attacking tumors without some of the usual side effects. The results, although not yet certain, point to prolonging the lives of breast cancer victims.
The treatment in clinical trials validates the method in which a drug is delivered to cancerous cells without harming healthy ones. “We’ve envisioned a world where cancer treatment would kill the cancer and not hurt the patient,” said Dr. Kimberly L. Blackwell, a professor of medicine at Duke Cancer Institute and a lead investigator in the clinical trial. Dr. Blackwell said this drug does that.
The drug, known as T-DM1, was developed by Genetech, which sponsored the trial. The company has indicated that it would ask for approval of the use of the drug later this year. That would mean the drug would be available for sale in 2013.